Connecticut Clinical Trials Report — May 2026

For Connecticut residents considering participation in clinical research, May 2026 presents a crucial window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 89 clinical trials are slated to conclude within the next 90 days. This urgency extends to healthy volunteers, with 15 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, metabolic disorders, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor
• Obesity
• Stage IV lung cancer AJCC V8
• Triple negative breast cancer
• Irritable bowel syndrome with constipation (IBS-C)
• Type 2 diabetes
• Advanced breast cancer
• Alcohol use disorder (AUD)
• Cannabis
• Infertility

These studies represent diverse areas of medical inquiry, offering participants the chance to contribute to research in fields ranging from oncology to mental health and reproductive medicine. Given the limited time, prospective volunteers are encouraged to act quickly.

A Closer Look at Connecticut's New Research Landscape

This month, Connecticut saw the opening of just 2 new clinical trials, a notable decrease compared to the 21 trials that launched in March 2026. While the number of new opportunities is lower this May, the state continues to offer a broad array of research, with a total of 1,253 clinical trials currently recruiting across 53 cities and 623 research sites.

The two new trials this month bring specific opportunities to participants. One new study is focused on chin augmentation, exploring advancements in cosmetic and reconstructive procedures. The other is a Phase 1 trial, typically the first stage of human testing for a new drug or treatment, designed to assess safety and dosage. Both of these new trials are sponsored by industry leaders, with one from Galderma R&D and the other from Pfizer, lending significant credibility to these research initiatives.

It is noteworthy that both of these new trials are accepting healthy volunteers, creating immediate opportunities for individuals without specific health conditions to participate in cutting-edge research. This aligns with a broader trend in Connecticut, where a total of 154 trials are currently recruiting healthy participants statewide.

Geographic Distribution of New Opportunities

The two new trials opening this month are located in key areas of Connecticut, enhancing accessibility for residents. One new trial is available in New Haven, a prominent hub for medical research and innovation. The other new trial is located in Westport, expanding research opportunities to a different part of the state.

While new trial openings are modest this month, Connecticut maintains a robust and geographically diverse clinical trial landscape. With studies actively recruiting across 53 cities and at 623 research sites, residents throughout the state have access to a wide range of research opportunities. This broad distribution helps ensure that participation in medical advancements is not limited to major metropolitan areas, but is accessible to many communities.

Who Can Participate in Connecticut's Trials?

Participation in clinical trials is open to a wide range of individuals, and this month's new trials reflect a commitment to inclusive research. Both of the new trials launched in May are actively seeking older adults as participants. This ensures that senior populations have ample opportunity to contribute to medical science, addressing health concerns relevant to their age group.

For individuals without a specific medical condition, there are significant opportunities to contribute. As mentioned, both of the new trials this month are actively seeking healthy volunteers. Across Connecticut, a total of 154 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research without having a diagnosed condition. These trials often contribute to understanding normal physiological processes, establishing baseline data, or testing preventive measures.

The new studies this month are exclusively industry-sponsored, with Galderma R&D and Pfizer leading these initiatives. This highlights the significant role that pharmaceutical and device companies play in driving medical innovation within Connecticut. These sponsors often bring substantial resources and expertise to the research landscape, contributing to the development of new treatments and technologies.

As we move forward, the focus will remain on the ongoing enrollment in the state's diverse portfolio of clinical trials, while researchers anticipate the next wave of innovative studies designed to address a broad spectrum of health challenges across Connecticut.